We recognized that endothelin B receptors in the brain are key to its development.
Evidence that a deficiency in endothelin B receptors leads to a poorer outcome and exacerbation of damage to the brain following cerebral ischemia suggests a role of endothelin B receptors in the pathophysiological process of ischemic stroke.
We broke new ground by selectively activating endothelin B receptors with PMZ-1620 to reduce the infarct volume and improve neurological functions following ischemic stroke.
PMZ-1620 is likely to offer significant advantages over existing products because it has been found to have anti-apoptotic, anti-inflammatory, and anti-oxidant activity thereby limiting the death of brain cells. It also promotes the formation of new neurons (neurogenesis) and new blood vessels (angiogenesis).
PMZ-1620 has a high safety profile, and is simply administered as an intravenous bolus injection.
Patents issued in United States, China, European Union and Japan.
Clinical stage – Phase I (CTRI/2016/11/007509) completed; Phase II (CTRI/2017/11/010654) completed.
Ischemic stroke (PMZ-1620)